




# SARS CoV 2 PT Scheme (SAR) Individual Report

SA004 - (Round 04) 01 Mar 2021

SA0493 - Fernanda Galo, Lda.

Issue Number: 1

Issued: 11/03/2021



Science  
for a safer world

**LGC Proficiency Testing**  
1 Chamberhall Business Park | Chamberhall Green | Bury | United Kingdom | BL9 0AP



0001

**Sample Details**

Samples were despatched: 25 January 2021

Reporting Deadline Date: 01 March 2021

The following samples were despatched in **Round SA004**:

**COV: Molecular****Sample**

<b>A</b>	Negative
<b>B</b>	Positive - approximately 7,500 copies per ml

-

**Comments**

Sample A was negative

Sample B contained the entire SARS-CoV-2 genome (minus replicative sequences). Therefore, there should have been no method or reagent incompatibilities experienced.

It should be noted that the sample contains non-replicant recombinant virus particles (and is not purely the RNA sequence) and is therefore a simulated clinical sample that should be treated as an actual clinical sample. Therefore, it should be extracted in the same way as a clinical sample.

Any laboratory who did not complete the usual extraction process may be expected to obtain a false negative result for Sample B as they would not have released the RNA.

**ATB: Antigen****Sample**

<b>A</b>	Positive
<b>B</b>	Positive
<b>C</b>	Negative

Sample A and B were proven positive for SARS-CoV-2 IgG. Sample C was proven negative.

## Individual Report

This individual report contains a summary of all the results submitted and the performance assessment for your laboratory/individual analysts. Please note that the nominated results for each analyte are indicated by the blue highlight in the analyst field.

Full details of the scheme, sample types and data analysis can be found in the corresponding Main Report, along with any technical comments, if applicable. The main report is the definitive version.

If you have any questions regarding your results which are not answered in the Main Report, please contact us using the details provided on the front of the report. If you would like to order any samples for re-testing please visit our web shop at [www.lgcstandards.com](http://www.lgcstandards.com) or contact your local LGC representative.

## Assessment Summary

Sample	Assessments Received	Satisfactory Assessments	Questionable Assessments	Unsatisfactory Assessments	Not Assessed
PT-CL-MI-ATG	3	3	0	0	0
Round Total	3	3	0	0	0

a

Result which are Not Assessed should be review by comparing them with the assigned value and other relevant statistics given in the main report. Participant, according to their internal quality criteria, may consider Not Assessed results to be satisfactory, questionable or unsatisfactory. Further information regarding why results may not be assessed is given in the Scheme Information section of the main report.

Repeat PT samples are normally available for purchase, after the completion of the round. These samples can be purchased at a reduced rate if you have taken this sample during the main round. Visit our web shop at [www.lgcstandards.com](http://www.lgcstandards.com) and search for the sample you require.

No unsatisfactory assessments in this round

No questionable assessments in this round

**ATG - SARS-CoV-2 Antigen**

Analyte	Result Field	Analyst	Method	Result	Assigned Value	Number of results	Satisfactory %	Your Reference
SARS-CoV-2	Sample A	Dr <sup>a</sup>	Other	Detected	Detected	13	100.0%	Panbio Covid-19 Ag Rapid Test
SARS-CoV-2	Sample B	Dr <sup>a</sup>	Other	Detected	Detected	13	100.0%	Panbio Covid-19 Ag Rapid Test
SARS-CoV-2	Sample C	Dr <sup>a</sup>	Other	Not detected	Not detected	13	100.0%	Panbio Covid-19 Ag Rapid Test